Shimizu Dai, Kanda Mitsuro, Kodera Yasuhiro
Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
World J Gastrointest Oncol. 2018 Jun 15;10(6):124-136. doi: 10.4251/wjgo.v10.i6.124.
Gastric cancer (GC) is one of the most frequently diagnosed cancers in the world. Most GC patients are diagnosed when the cancer is in an advanced stage, and consequently, some develop metastatic lesions that generally cause cancer-related death. Metastasis establishment is affected by various conditions, such as tumor location, hemodynamics and organotropism. While digestive cancers may share a primary site, certain cases develop hematogenous metastasis with the absence of peritoneal metastasis, and vice versa. Numerous studies have revealed the clinicopathological risk factors for hematogenous metastasis from GC, such as vascular invasion, advanced age, differentiation, Borrmann type 1 or 2 and expansive growth. Recently, molecular mechanisms that contribute to metastatic site determination have been elucidated by advanced molecular biological techniques. Investigating the molecules that specifically participate in metastasis establishment in distinct secondary organs will lead to the development of novel biomarkers for patient stratification according to their metastatic risk and strategies for preventing and treating distinct metastases. We reviewed articles related to the molecular landscape of hematogenous metastasis from GC.
胃癌(GC)是世界上最常被诊断出的癌症之一。大多数GC患者在癌症处于晚期时才被诊断出来,因此,一些患者会出现转移病灶,这通常会导致癌症相关死亡。转移的形成受多种因素影响,如肿瘤位置、血流动力学和器官趋向性。虽然消化系统癌症可能有共同的原发部位,但某些病例会发生血行转移而无腹膜转移,反之亦然。许多研究已经揭示了GC血行转移的临床病理危险因素,如血管侵犯、高龄、分化程度、Borrmann 1型或2型以及膨胀性生长。最近,先进的分子生物学技术已经阐明了有助于确定转移部位的分子机制。研究在不同继发器官中特异性参与转移形成的分子,将有助于开发新的生物标志物,以便根据患者的转移风险对其进行分层,并制定预防和治疗不同转移的策略。我们综述了与GC血行转移分子格局相关的文章。